Document is current
Any future updates will be listed below
-
Authors
Peloquin, Sophie
Cymbalista, Florence
Dreyling, Martin
Shah, Nirav N.
Murray, Suzanne
Del Fiacco, Romano
Muehlenbein, Catherine E.
Lazure, Patrice
- License Information
-
More Information
Article History
Received: 12 February 2024
Accepted: 1 August 2024
First Online: 13 August 2024
Declarations
:
: All components of this study were approved by an international independent ethical review board (Veritas IRB, Canada, Tracking Number 2021-2930-9264-1), and all participants agreed to informed consent forms describing the nature and confidentiality of their participation, as well as their rights as a participant.
: Not applicable.
: SP and PL are employees of AXDEV Group Inc. SM is CEO & founder of AXDEV Group Inc., AXDEV Global Inc., and AXDEV Europe GmbH. NS reports participation on advisory boards and/or consultancy for Kite Pharma, BMS-Juno, TG therapeutics, Miltenyi Biotec, Lilly-LOXO, Epizyme, Incyte, Novartis, Janssen, Seattle Genetics, and Umoja; and research funding and honoraria from Miltenyi Biotec.FC reports participation on advisory boards and/or consultancy for AbbVie, Lilly, Janssen, Astra Zeneca.MD reports participation on advisory boards for Astra Zeneca, Beigene, BMS/Celgene, Gilead/Kite, Janssen, Lilly/Loxo, Novartis, Roche. He has research funding from Abbvie, Bayer, BMS/Celgene, Gilead/Kite, Janssen, Roche, and honoraria from Astra Zeneca, Beigene, Gilead/Kite, Janssen, Lilly, Novartis, Roche. MD is an associate editor for HemaSphere. NS, FC, and MD received research honoraria from AXDEV Global for their contribution to the study design, review of research tools, and interpretation of the findings from this study. RDF and CEM are employees of Eli Lilly and Company.
